Choosing Appropriate Glucagon-like Peptide 1 Receptor Agonists: A Patient-Centered Approach

Diabetes Therapy

Volumn 5, Issue 1, 2014, Pages 333-340

  Kalra, Sanjay ^a  

^a India   (India)

Author keywords

GLP1RAs; Glucagon like peptide 1 receptor agonists; Patient centered; Type 2 diabetes

Indexed keywords

ALBIGLUTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN DEGLUDEC PLUS LIRAGLUTIDE; INSULIN GLARGINE; LIRAGLUTIDE; LIXISENATIDE; SEMAGLUTIDE;

ANTIBODY PRODUCTION; ANXIETY; ARTICLE; CHRONOTROPISM; DIRECTLY OBSERVED THERAPY; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; LIPID BLOOD LEVEL; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PRIORITY JOURNAL; PSYCHOLOGICAL WELL BEING; PSYCHOSOCIAL CARE; STOMACH PARESIS; SYSTOLIC BLOOD PRESSURE; WEIGHT REDUCTION;

EID: 84922829393     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-014-0058-y     Document Type: Article

References (38)

1. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32:84–90.
2. Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care. 2003;26:2370–7.
3. Werner U, Haschke G, Herling AW, Kramer W. Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regul Pept. 2010;164:58–64.
4. Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, et al. One week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and α- and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 2004;53:1187–94.
5. Matthews JE, Stewart MW, De Boever EH, Dobbins RL, Hodge RJ, Walker SE, et al. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. Clin Endocrinol Metab. 2008;93:4810–7.
6. Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2007;30:1487–93.
7. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. Clin Endocrinol Metab. 2003;88:3082–9.
8. Knudsen LB, Nielsen PF, Huusfeldt PO, Johansen NL, Madsen K, Pedersen FZ, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem. 2000;43:1664–9.
9. Bush MA, Matthews JE, De Boever EH, Dobbins RL, Hodge RJ, Walker SE, et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. Diabetes Obes Metab. 2009;11:498–505.
10. Glaesner W, Vick AM, Millican R, Ellis B, Tschang SH, Tian Y, et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes. 2010;26:287–96.
11. Barrington P, Chien JY, Tibaldi F, Showalter HD, Schneck K, Ellis B. LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects. Diabetes Obes Metab. 2011;13:434–8.
12. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39–47.
13. Kendall DM, Kim DD, Riddle MC, Fineman MS, Rosenstock J, Baron AD, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083–91.
14. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628–35.
15. Defronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092–100.
16. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005;143:559–69.
17. Gerich JE, Fonseca VA, Alvarado-Ruiz R, Raccah D, Zieleniuk I, Boka G, et al. Monotherapy with GLP-1 receptor agonist, lixisenatide, significantly improves glycaemic control in type 2 diabetic patients [abstract 830]. Diabetologia. 2010;53(Suppl 1):S330.
18. Ratner RE, Saubadu S, Dimaz AL, Aronson R, Miossec P, et al. Efficacy and safety of lixisenatide once-daily versus placebo in patients with type 2 diabetes mellitus insufficiently controlled on sulfonylurea ± metformin (Get Goal-S.) [abstract 785]. Diabetologia. 2011;54:S317.
19. Rosenstock J, Christensen M. Efficacy and safety of lixisenatide once-daily versus exenatide twice-daily in patients with type 2 diabetes insufficiently controlled on metformin (GetGoal-X) [abstract 786]. Diabetologia. 2011;54:S317.
20. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Patti H, Lover-Alvarez I, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473–81.
21. Marre M, Shaw J, Brändle M, Bebakar WM, Kamaruddin NA, Strand J, et al. Liraglutide, a once-daily human GLP–1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26:268–78.
22. Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD). Diabetes Care. 2009;32:1224–30.
23. Buse JB, Garber A, Rosenstock J, Schmidt WE, Brett JH, Videbæk N, et al. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. J Clin Endocrinol Metab. 2011;96:1695–702.
24. Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374:1606–16.
25. GSK receives initial data from the first completed phase lll study of albiglutide in type 2 diabetes. GlaxoSmithKline (online); 2011. http://www.gsk.com/media/pressreleases/2011/2011-pressrelease-742869.htm. Accessed 15 Dec, 2013.
26. Rosenstock J, Reusch J, Bush M, Yang F, Stewart M. The potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing [abstract]. Diabetes. 2009;59:163-OR.
27. Stewart MW, Reusch JE, Bush MA, Yang F, Rosenstock J. The gastrointestinal adverse event profile of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes [abstract]. Diabetes. 2009;59:598-P.
28. Umpierrez GE, Blevins T, Rosenstock J, Cheng C, Anderson JH, Bastyr EJ. The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study. Diabetes Obes Metab. 2011;13:418–25.
29. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372:1240–50.
30. Diamant M, Van Gaal L, Stranks S, Northrup J, Cao D, Taylor K, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010;375:2234–43.
31. Bergenstal RM, Wysham C, Macconell L, Malloy J, Walsh B, Yan P, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010;376:431–9.
32. Blevins T, Pullman J, Malloy J, Yan P, Taylor K, Schulteis C, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96:1301–10.
33. Fineman MS, Cirincione BB, Maggs D, Diamant M. GLP-1 based therapies: differential effects on fasting and postprandial glucose. Diabetes Obes Metab. 2012;14:675–88.
34. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8:728–42.
35. Lorenz M, Pfeiffer C, Steinsträßer A, Ruus P. Effects of lixisenatide once daily on gastric emptying and relationship to postprandial glycemia in type 2 diabetes mellitus (Abstract). Diabetes. 2012;61(Suppl 1):A280.
36. Pratley R, Nauck M, Bailey T, Monataya E, Cudihhy R, Filleti S, et al. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract. 2011;65:397–407.
37. Grant P, Lipscomb D, Quin J, et al. Psychological and quality of life changes in patients using GLP-1 analogues. J Diabetes Complications. 2011;25:244–6.
38. Bode BW, Testa MA, Magwire M, Hale PM, Hammer M, Blonde L, et al. Patient reported outcomes with following treatment with human GLP-1 analogue liraglutide or glimiperide in monotherapy: results from a randomised controlled trial in patients with type 2 diabetes. Diabetes Obes Metab. 2010;64:604–12.